BioNTech SE reported second-quarter revenue of €260.8 million, more than doubling from a year earlier and outperforming analyst expectations of roughly €149 million, as demand for its COVID-19 vaccine rebounded ahead of an expected U.S. regulatory decision on an updated shot. The German company posted a net loss of €386.6 million, or €1.60 per share, and an operating loss of €501.1 million—smaller than the loss analysts had projected. BioNTech ended June with €16 billion in cash, cash equivalents and securities, giving it ample capacity to finance research and acquisitions. Management reaffirmed 2025 guidance of €1.7 billion to €2.2 billion in revenue and €2.6 billion to €2.8 billion in operating expenses, despite consensus forecasts sitting at the high end of the range. The company highlighted progress in oncology, including its BNT327 program, and said the recently announced acquisition of partner CureVac will broaden its mRNA cancer-immunotherapy pipeline.